SCHEMBL6078477

SCHEMBL6078477

CCNC(=O)c1ccc(CCl)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
LMNA P02545 2/20 0.56
MAPT P10636 1/20 0.56
HPGD P15428 1/20 0.56
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
PLK1 P53350 2/20 0.50
ALDH1A1 P00352 2/20 0.49
POLB P06746 2/20 0.49
CTDSP1 Q9GZU7 2/20 0.49
KDM4E B2RXH2 1/20 0.49
GAA P10253 1/20 0.49
ACACB O00763 1/20 0.48
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
CA12 O43570 1/20 0.47
CA9 Q16790 1/20 0.47
HSP90AA1 P07900 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5909057 0.85 CA12 (0.58) MEN1KMT2ALMNAMAPTHPGD
SCHEMBL21674205 0.84 CA1 (0.55) MEN1KMT2ALMNAMAPTCA1
SCHEMBL826023 0.84 PLK1 (0.68) MEN1KMT2ALMNAMAPTHPGD
SCHEMBL20300540 0.84 L3MBTL1 (0.61) HPGDCA2PLK1ALDH1A1HDAC3
SCHEMBL10789232 0.82 EPHX2 (0.60) MEN1KMT2ALMNAMAPTHPGD
SCHEMBL10951282 0.82 PLK1 (0.72) MEN1KMT2ALMNAMAPTHPGD
SCHEMBL20300413 0.81 L3MBTL1 (0.71) MEN1KMT2AMAPTHPGDCA2
SCHEMBL20679857 0.81 L3MBTL1 (0.71) MEN1KMT2AMAPTHPGDCA2
SCHEMBL1854109 0.81 L3MBTL1 (0.71) MEN1KMT2AMAPTHPGDCA2
SCHEMBL21104562 0.81 HDAC1 (0.60) LMNAMAPTCA1CA2PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors FLECK ROMAN WOLFGANG 2009-09-10 US disclosed
US-7084178-B2 Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2006-08-01 US disclosed
WO-2005054180-A1 ANTIAMYLOID PHENYLSULFONAMIDES: N-CYCLOALKYLCARBOXAMIDES DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2005-06-16 WO disclosed
US-20050113442-A1 Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives BRISTOL-MYERS SQUIBB COMPANY 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors EPHX1, EPHX2, EPX MEN1 4409/4885KMT2A 3792/4885LMNA 1843/4885
US-20050113442-A1 Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives APP, PSEN1, PSEN2 MEN1 4607/4885KMT2A 4497/4885LMNA 1191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.